drugset
drugset / Trial / NCT00634361

Ethyl-EPA Treatment of Prodromal Patients

NCT00634361 ↗

Phase 2/3 Completed 7 enrolled Yale University
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label trial of an omega-3 fatty acid for symptoms of the schizophrenia prodrome.

Timeline

Start
2001-09
Primary completion
2005-08
Completion
2005-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Ethyl Eicosapentaenoic Acid Unknown 2 mg —

Indications

schizophrenia